gefitinib has been researched along with tyrphostin ag825 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tyrphostin ag825) | Trials (tyrphostin ag825) | Recent Studies (post-2010) (tyrphostin ag825) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 45 | 0 | 16 |
| Protein | Taxonomy | gefitinib (IC50) | tyrphostin ag825 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.35 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.3484 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arteaga, CL; Boimel, PJ; Coniglio, SJ; Hynes, NE; Kedrin, D; Segall, JE; Wyckoff, J | 1 |
1 other study(ies) available for gefitinib and tyrphostin ag825
| Article | Year |
|---|---|
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Movement; ErbB Receptors; Female; Gefitinib; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |